| "A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies " |
Ongoing |
HYDROXYUREA (HYDROXYCARBAMIDE) |
3 |
CT20/008/R |
King Abdulaziz Medical City NG (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Ongoing |
Convalescent Plasma |
2 |
20-COVID-19-01M |
KFSH-D |
| A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors. |
Ongoing |
Mim8 |
3 |
NN7769-4514 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes " |
Terminated |
GLIMEPIRIDE-HOE490 |
3 |
GLIME_R_05809 |
KFSH |
| A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR) |
Completed |
Tezepelumab |
3 |
D5180C00007 |
KAUH-J |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) |
Ongoing |
Tezepelumab |
3 |
D5180C00018 |
KAUH-J |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome |
Rejected |
Alogliptin |
3 |
SYR-322_402 |
PSMMC |
| A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation |
Ongoing |
AMG 510 (Sotorasib) |
3 |
20190436 |
King Fahad Specialist Hospital (Dammam) |
| A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer |
Completed |
Pertuzumab + Trastuzumab +Taxane |
3 |
MO28047 |
KFSH & RC-R |
| A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
BMN 110 |
3 |
MOR-005 |
KFSH & RC-R |
